Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Dow
Harvard Business School
McKesson
Boehringer Ingelheim
Mallinckrodt
Express Scripts

Last Updated: October 18, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for PF-06649751

See Plans and Pricing

« Back to Dashboard

Development status for investigational drug PF-06649751: Sponsors, patents, clinical trial progress

PF-06649751 is an investigational drug.

There have been 8 clinical trials for PF-06649751. The most recent clinical trial was a Phase 1 trial, which was initiated on October 1st 2016.

The most common disease conditions in clinical trials are Parkinson Disease and [disabled in preview]. The leading clinical trial sponsors are Pfizer and [disabled in preview].

There are nine US patents protecting this investigational drug and sixty-nine international patents.

Recent Clinical Trials for PF-06649751
TitleSponsorPhase
Safety and Tolerability of PF-06649751 in Parkinson's Disease Patients With Motor FluctuationsPfizerPhase 2
Efficacy, Safety and Tolerability of PF-06649751 in Parkinson's Disease Patients at Early Stage of the DiseasePfizerPhase 2
Efficacy, Safety and Tolerability of PF-06649751 in Parkinson's Disease Patients With Motor FluctuationsPfizerPhase 2

See all PF-06649751 clinical trials

Clinical Trial Summary for PF-06649751

Top disease conditions for PF-06649751
Top clinical trial sponsors for PF-06649751

See all PF-06649751 clinical trials

US Patents for PF-06649751

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
PF-06649751   Start Trial Heteroaromatic compounds and their use as dopamine D1 ligands Pfizer Inc. (New York, NY)   Start Trial
PF-06649751   Start Trial 1,5-naphthyridine derivatives and MELK inhibitors containing the same OncoTherapy Science, Inc. (Kanagawa, JP)   Start Trial
PF-06649751   Start Trial Heteroaromatic compounds and their use as dopamine D1 ligands Pfizer Inc. (New York, NY)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
McKesson
McKinsey
Express Scripts
Johnson and Johnson
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.